If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Once we draw out the potential stereoisomers, we see that the two structures are super-imposable in three dimensions, and therefore are the self-same molecule. For this reason fentanyl does not have R/S assignments. The second case studied here is of 3-methylfentanyl. There are two potential stereocenters, at the 4-carbon and also at the 3-carbon, where there is additionally a methyl group. Now, we mark both 3 and 4 carbon as potential stereocenters with an asterisk (*), and see how many potential stereoisomers we can eliminate. We see that of the four permutations of stereoisomers, none are super-imposable in three dimensions, meaning each is a unique stereoisomer and that both potential stereocenters were true. This gives four potential R/S assignments, 1R3S, 1R3R, 1S3S, 1S3R. What is particularly interesting and quite a contrast from the previous example of cyclohexanol, is the stereocenter at C-4 is indeed a true stereocenter here, whereas in the previous example of cyclohexanol as an analogy to fentanyl, the C-4 was not a true stereocenter. This changed because the modification of the C-3 carbon without an equivalent change on the C-2 carbon created an imbalance between two formerly identical substituents, creating a novel stereocenter where there was not one previously. This is why it is so important to follow the 4 steps in the above procedure every time, as "inherited procedural wisdom" may hold an organic chemist back in finding the true or correct answer.
fluorescence in situ hybridization (FISH) A type of in situ hybridization assay where the oligonucleotide probes are labelled with a chemical compound that is naturally fluorescent when exposed to light at particular wavelengths, making it possible to detect the in situ locations of complementary sequences with fluorescence microscopy. FISH is commonly used to visualize the physical locations of specific genes on chromosomes.
=== Pharmacogenomics === Genetic factors explain 49% of the pain response variance in the cold pressor test. Further the response variance to analgesia using alfentanil in the cold pressor test can be attributed to genetic effects at 60%. Morphine and its metabolites directly interact with several proteins, including: UGT2B7, OCT1 (SLC22A1), μ-opioid receptor (OPRM1), and P-glycoprotein (ABCB1 or MDR1). Furthermore catechol-O-methyltransferase indirectly affects efficacy of morphine.
=== Veterinary use === Veterinary clinics use cold laser devices to treat a wide variety of ailments, from arthritis to wounds, on dogs and cats. In spite of this, little research has been done on its effects. According to Brennen McKenzie, president of the Evidence-Based Veterinary Medicine Association, as of 2016 "research into cold laser in dogs and cats is sparse and generally low quality. Most studies are small and have minimal or uncertain controls for bias and error". He allowed that some studies show promising results, while concluding that current evidence is not sufficient to support routine clinical use.
Sources: en.wikipedia.org
Researchers were able to identify differences in acacia and polyfloral honeys by the differing proportions of fructose and sucrose, as well as differing levels of aromatic amino acids phenylalanine and tyrosine. This ability allows greater ease of selecting compatible stocks.
The extremely powerful radio transmissions needed for such a system led to much disruption of civilian shortwave broadcasts, earning it the nickname "Russian Woodpecker". The idea that any nuclear conflict would eventually escalate was a challenge for military strategists. This challenge was particularly severe for the United States and its NATO allies. It was believed (until the 1970s) that a Soviet tank offensive into Western Europe would quickly overwhelm NATO conventional forces, leading to the necessity of the West escalating to the use of tactical nuclear weapons, one of which was the W-70. This strategy had one major (and possibly critical) flaw, which was soon realized by military analysts but highly underplayed by the U.S. military: conventional NATO forces in the European theatre of war were far outnumbered by similar Soviet and Warsaw Pact forces, and it was assumed that in case of a major Soviet attack (commonly envisioned as the "Red tanks rolling towards the North Sea" scenario) that NATO—in the face of quick conventional defeat—would soon have no other choice but to resort to tactical nuclear strikes against these forces. Most analysts agreed that once the first nuclear exchange had occurred, escalation to global nuclear war would likely become inevitable. The Warsaw Pact's vision of an atomic war between NATO and Warsaw Pact forces was simulated in the top-secret exercise Seven Days to the River Rhine in 1979. The British government exercised their vision of a Soviet nuclear attack with Square Leg in early 1980.
=== Cancer immunotherapy === Garcia has conducted several studies targeting cellular receptors for applications in cancer immunotherapy. In 2013, Garcia's group developed high affinity antagonists of the receptor CD47 that potently enhance the antitumor effects of established therapeutic antibodies. Garcia later determined that the therapeutic effects of CD47 blockade require combination therapy with checkpoint blockade antibodies in immunocompetent hosts, thus proving that CD47-based therapy relies upon stimulation of the adaptive immune system. Garcia's lab published the creation of an "orthogonal" IL-2 receptor complex to enable the selective delivery of IL-2 signals to engineered T cells during adoptive cell therapy. They also reported a new technology using yeast-displayed peptide-MHC molecules to identify tumor antigens recognized by Tumor Infiltrating Lymphocytes.
== Fecundity == Fecundity of An. gambiae depends on the detoxification of reactive oxygen species (ROS) by catalase. Reduction in catalase activity significantly reduces reproductive output of female mosquitoes, indicating that catalase plays a central role in protecting oocytes and early embryos from ROS damage.
=== Before 1873 === Prior to Japan adopting the Gregorian calendar, it used the lunisolar Japanese calendar. The first five years of the era correspond to the following date ranges in the Gregorian calendar:
Sources: en.wikipedia.org
=== The cellular response to infection === Circulating hemocytes are key regulators of infection. This has been demonstrated both through genetic tools to generate flies lacking hemocytes, or through injecting microglass beads or lipid droplets that saturate hemocyte ability to phagocytose a secondary infection. Flies treated like this fail to phagocytose bacteria upon infection, and are correspondingly susceptible to infection. These hemocytes derive from two waves of hematopoiesis, one occurring in the early embryo and one occurring during development from larva to adult. However Drosophila hemocytes do not renew over the adult lifespan, and so the fly has a finite number of hemocytes that decrease over the course of its lifespan. Hemocytes are also involved in regulating cell-cycle events and apoptosis of aberrant tissue (e.g. cancerous cells) by producing Eiger, a tumor necrosis factor signalling molecule that promotes JNK signalling and ultimately cell death and apoptosis.
== Size of listings == The size of the darknet markets economy can be problematic to estimate. A study based on a combination of listing scrapes and feedback to estimate sales volume by researchers at Carnegie Mellon University captured some of the best data. A reviewed 2013 analysis put the Silk Road grossing $300,000 a day, extrapolating to over $100 million over a year. Subsequent data from later markets has significant gaps as well as complexities associated with analysing multiple marketplaces.
Despite getting a late start in publishing his research (he did not publish a paper until 10 years after finishing graduate school), Fenn had over 100 publications at the time of his death. He also wrote a book, entitled Engines, Energy, and Entropy: A Thermodynamics Primer. The Science History Institute Museum in Philadelphia, PA has the instrument Fenn and his graduate students built while they were developing electrospray ionization on display, after receiving it as a gift from Fenn.
Prednisolone is a corticosteroid, a steroid hormone used to treat certain types of allergies, inflammatory conditions, autoimmune disorders, and cancers, electrolyte imbalances, and skin conditions. Some of these conditions include adrenocortical insufficiency, high blood calcium, rheumatoid arthritis, dermatitis, eye inflammation, asthma, multiple sclerosis, and phimosis. It can be taken by mouth, injected into a vein, used topically as a skin cream, or as eye drops. Common side effects with short-term use include nausea, difficulty concentrating, insomnia, increased appetite, and fatigue. More severe side effects include psychiatric problems, which may occur in about 5% of people. Common side effects with long-term use include bone loss, weakness, yeast infections, and easy bruising. While short-term use in the later part of pregnancy is safe, long-term use or use in early pregnancy is occasionally associated with harm to the baby. It is a glucocorticoid made from hydrocortisone (cortisol). Prednisolone was discovered and approved for medical use in 1955. It is on the World Health Organization's List of Essential Medicines. It is available as a generic drug. In 2023, it was the 146th most commonly prescribed medication in the United States, with more than 3 million prescriptions.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.